TMVR

TENDYNE™ TRANSCATHETER MITRAL VALVE REPLACEMENT

Tendyne™ TMVR System is first-in-class technology designed to eliminate mitral regurgitation (MR), offering select patients with MR (≥ grade 3), a novel option for mitral valve replacement.

First-in-class technology that eliminates mitral regurgitation (MR) in select patients 

Tendyne™ transcatheter mitral valve replacement (TMVR) improves your patients' function and quality of life by offering select patients with symptomatic, significant MR (≥ grade 3) a less invasive mitral valve replacement option over conventional mitral valve surgery. Tendyne TMVR provides symptom relief by eliminating MR.1

  • Beating heart procedure without the need for cardiopulmonary bypass or rapid pacing
  • Complete MR elimination in 99% of patients at 30 days1
  • Sustained MR elimination in 93% of patients at 2 years1
  • 96% technical success rate1,*
  • System is fully repositionable and retrievable at any point intraprocedurally
  • Significant improvement in symptom and quality-of-life measures1
  • Low mean mitral gradient of 3.2 mm Hg at 2 years1

*Technical success per Mitral Valve Academic Research Consortium (MVARC).

MR is the most common valvular heart disease and is significantly undertreated3

More patients are suffering from MR than any other valve disease, and only a small percentage of them are treated.2,*,† Significant MR is 4 times more prevalent than significant aortic stenosis.3,4

 

*Calculations are approximations made based on data from Mills J, Furlong C. CANACCORD: Biomedical Devices and Services. Nov 8, 2016 and Millennium Research Group. US Markets for Heart Valve Devices 2014. 2013;   RPUS12HV13:92; and data from Abbott (LRP 20161130; based on LBE4) and Millennium Research Group. US Markets for Heart Valve Devices 2014. 2013;RPUS12HV13:94,153.
Patients treated defined as undergoing surgery or transcatheter procedure.

  • Solutions are needed beyond surgery

    In one survey, almost 50% of symptomatic patients with severe MR were not candidates for mitral valve surgery due to underlying factors, including5,*:

    • Impaired left ventricle (LV) ejection fraction
    • High operative risk
    • Multiple comorbidities
    • Advanced age
    • For these patients most in need of intervention, medical management is not enough.

     

    *Based on a survey of severely symptomatic MR patients in New York Heart Association (NYHA) Class ≥ II+ (n = 396); 10% had surgery the following year. The remainder had no surgery and received medical management only.

  • Greater MR reduction is associated with higher survival

    Real world evidence shows significant relationship between degree of residual MR and survival after transcatheter mitral repair. Tendyne is an option for select MR patients who may benefit from MR elimination.6

    Post-Procedural Mitral Regurgitation6
    From United States TVT registry

Tendyne™ TMVR offers patients with severe MR (grade ≥3) a new option for safe and effective mitral valve replacement.

Safety and effectiveness of the Tendyne device have not been established in pediatric patients.

Designed for the mitral anatomy to eliminate MR

Valve

Dual-frame design provides customized anatomic fit and maintains stable hemodynamic performance

Inner frame

Circular self-expanding, tri-leaflet, bioprosthetic valve

Outer frame

Contoured design respects the shape of the native mitral valve for secure fixation and seal

3D FLEXIBILITY. INFINITE POSSIBILITY

Tether

High degree of device positioning control, including full retrievability at any point intraoperatively

Pad

Placed over the access site and associated with a low rate of complications7

TREAT MORE MR

Implant with confidence9

  • A wide array of sizes to provide appropriate fit for paravalvular sealing and LVOT area
    • AP dimension (mm): 26.4 - 41.3
    • Perimeter (mm): 96 - 143
  • Repositionable and retrievable intraoperatively, even after the valve is deployed
  • Robust pre-procedural planning support  

MAT-2000613 v6.0 | Item approved for OUS use only.

Copyright © 2022 Abbott, 3200 Lakeside Dr, Santa Clara, 95054, U.S.A.
Caution: These products are intended for use by or under the direction of a physician. Prior to use, reference the Instructions for Use, inside the product carton (when available) or at eifu.abbottvascular.com or at medical.abbott/manuals for more detailed information on Indications, Contraindications, Warnings, Precautions and Adverse Events.
Illustrations are artist’s representations only and should not be considered as engineering drawings or photographs. Photos on file at Abbott.
Unless otherwise specified, all product names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates.
No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.

MAT-2000631 v10.0 | Item approved for OUS use only.

YOU ARE ABOUT TO ENTER AN ABBOTT COUNTRY OR REGION SPECIFIC WEBSITE.

Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of the product that are not approved in other countries or regions.

YOU ARE ABOUT TO LEAVE
www.structural­heart.abbott

You are now leaving www.structuralheart.abbott. Abbott is not responsible for any content published on the third-party website you are about to enter. Abbott has not reviewed and does not endorse any information presented on third-party websites.